NDAINJECTIONINJECTABLE
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER (ceftriaxone) by B. Braun is 12. First approved in 2005.
Drug data last refreshed 36m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ceftriaxone and dextrose in duplex container is a third-generation cephalosporin antibiotic supplied in a ready-to-mix IV formulation designed for bacterial infections requiring parenteral therapy. It works by inhibiting bacterial cell wall synthesis, making it effective against a broad spectrum of gram-positive and gram-negative organisms. The duplex container format enables point-of-use reconstitution, improving medication safety and workflow efficiency in hospital settings.
LOE Approaching
As LOE approaches, the brand team is likely consolidating around defensive positioning and hospital channel strategies with smaller, specialized sales and marketing units.
Mechanism of Action
12.1 Mechanism of Action Ceftriaxone is an antibacterial drug [see ]. 12.3 Pharmacokinetics Average plasma concentrations of ceftriaxone following a single 30-minute intravenous (IV) infusion of a 0.5, 1 or 2 g dose in healthy subjects are presented in Table 2. Multiple IV doses ranging from 0.5 to…
Worked on CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.